India
· Delayed Price · Currency is INR Alkem Laboratories Statistics
Total Valuation
Alkem Laboratories has a market cap or net worth of INR 619.02 billion. The enterprise value is 615.09 billion.
| Market Cap | 619.02B |
| Enterprise Value | 615.09B |
Important Dates
The next estimated earnings date is Friday, February 7, 2025.
| Earnings Date | Feb 7, 2025 |
| Ex-Dividend Date | Aug 9, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 37.27M |
Valuation Ratios
The trailing PE ratio is 29.17.
| PE Ratio | 29.17 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 5.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.61, with an EV/FCF ratio of 40.86.
| EV / Earnings | 28.98 |
| EV / Sales | 4.79 |
| EV / EBITDA | 23.61 |
| EV / EBIT | 26.68 |
| EV / FCF | 40.86 |
Financial Position
The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.66 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.57 |
| Debt / FCF | 0.98 |
| Interest Coverage | 29.74 |
Financial Efficiency
Return on equity (ROE) is 19.53% and return on invested capital (ROIC) is 11.50%.
| Return on Equity (ROE) | 19.53% |
| Return on Assets (ROA) | 8.99% |
| Return on Capital (ROIC) | 11.50% |
| Revenue Per Employee | 7.36M |
| Profits Per Employee | 1.22M |
| Employee Count | 17,432 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.79% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +5.79% |
| 50-Day Moving Average | 5,489.78 |
| 200-Day Moving Average | 5,479.81 |
| Relative Strength Index (RSI) | 37.95 |
| Average Volume (20 Days) | 1,433 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alkem Laboratories had revenue of INR 128.32 billion and earned 21.22 billion in profits. Earnings per share was 177.51.
| Revenue | 128.32B |
| Gross Profit | 80.13B |
| Operating Income | 23.06B |
| Pretax Income | 24.22B |
| Net Income | 21.22B |
| EBITDA | 25.78B |
| EBIT | 23.06B |
| Earnings Per Share (EPS) | 177.51 |
Balance Sheet
The company has 22.89 billion in cash and 14.78 billion in debt, giving a net cash position of 8.11 billion.
| Cash & Cash Equivalents | 22.89B |
| Total Debt | 14.78B |
| Net Cash | 8.11B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 119.10B |
| Book Value Per Share | 961.30 |
| Working Capital | 69.32B |
Cash Flow
In the last 12 months, operating cash flow was 19.55 billion and capital expenditures -4.50 billion, giving a free cash flow of 15.05 billion.
| Operating Cash Flow | 19.55B |
| Capital Expenditures | -4.50B |
| Free Cash Flow | 15.05B |
| FCF Per Share | n/a |
Margins
Gross margin is 62.44%, with operating and profit margins of 17.97% and 16.54%.
| Gross Margin | 62.44% |
| Operating Margin | 17.97% |
| Pretax Margin | 18.87% |
| Profit Margin | 16.54% |
| EBITDA Margin | 20.09% |
| EBIT Margin | 17.97% |
| FCF Margin | 11.73% |
Dividends & Yields
This stock pays an annual dividend of 40.00, which amounts to a dividend yield of 0.76%.
| Dividend Per Share | 40.00 |
| Dividend Yield | 0.76% |
| Dividend Growth (YoY) | -20.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 22.53% |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.77% |
| Earnings Yield | 3.43% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |